BCR-ABL inhibitor
Catalog No. A03-901B
| Catalog No. | Pack Size | Price (USD) | |
|---|---|---|---|
| A03-901B-20 | 20 mg | $45 | |
| A03-901B-100 | 100 mg | $105 | |
| A03-901B-BULK | BULK | Contact Us |
Overview:
Tyrosine kinase inhibitor specific for bcr-abl (IC50 = 38 nM) (1), PDGF-R (IC50 = 0.3 uM) (1) and c-kit (IC50 = 0.1 uM) (2). It is a clinically useful anti-cancer drug approved for the treatment of chronic myelogenous leukemia (3), gastrointestinal stromal tumors as well as several other cancers.
References:
1. E Buchdunger et al. Cancer Res. 1996 56:100
2. Heinrich et et al. Blood 2000 96:925
3. M Deininger et al. Pharmacol. Rev. 2003 55:401
CAS Registry Number:
220127-57-1
Molecular Formula:
C29H31N7O · CH3SO3H
Appearance:
White solid
Melting Point:
N/A
Molecular Weight:
589.7
Purity:
98% (TLC); NMR (Conforms)
Solubilization:
May be dissolved in DMSO (50 mg/ml); or water (50 mg/ml)
Aliases:
1. 4-[(4-Methyl-1-piperazinyl) methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl] benzamide methanesulfonate
2. STI-571
Storage and Stability:
Store desiccated as supplied at -20°C for up to 1 year. Store solutions at -20°C for up to 3 months.
Molecular Structure:
|
Cancer
STAY CONNECTED
Fax: 1-604-232-4601
Friedman R et al., The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib BMC Cancer May 2020 10.1186/s12885-020-06782-9
Toll Free: 1-866-954-6273
info@signalchem.com